Clinical trials: Non-valvular Atrial Fibrillation (NVAF)
Non-valvular Atrial Fibrillation (NVAF), Venous Thromboembolism (VTE)
Precision Antithrombotic Therapy
The goal of this observational study is to systematically analyze the relationship between trough/peak concentrations of novel oral anticoagulants (NOACs) and antiplatelet drugs with clinical events, aiming to provide high-level…
- Conditions
- Non-valvular Atrial Fibrillation (NVAF), Venous Thromboembolism (VTE), MI(Myocardial Infarction), Ischemic Stroke
- Trial name
- NCT07654634
- Testing
- Not applicable- observational study
- Where
- China
- Volunteers
- 5,000 people
- Sponsor
- The Third Xiangya Hospital of Central South University
Non-valvular Atrial Fibrillation (NVAF)
FIM Study of the LAmbre™ II LAA Occluder in Non-Valvular AF Patients
To evaluate the preliminary safety and feasibility of the LAmbreTM II Left Atrial Appendage Occluder and the Occluder Delivery System in patients with non-valvular atrial fibrillation who are at increased risk for stroke and…
- Trial name
- NCT07385599
- Testing
- LAmbre™ II Left Atrial Appendage Occluder and Occluder Delivery System
- Where
- Hong Kong
- Volunteers
- 10 people
- Sponsor
- Lifetech Scientific (Shenzhen) Co., Ltd.
Non-Valvular Atrial Fibrillation (NVAF)
A Study Evaluating the Associations Between Clinical Characteristics and Use of Oral Anticoagulants in Italian Elderly Participants With Non-Valvular Atrial Fibrillation
The purpose of this study is to provide real-world data useful to address the factors associated to the administration of oral anticoagulants in the elderly population affected by non-valvular atrial fibrillation (NVAF), in…
- Trial name
- PRESBUS (NCT05232643)
- Where
- Italy
- Volunteers
- 636 people
- Sponsor
- Bristol-Myers Squibb
Non-valvular Atrial Fibrillation (NVAF), Thromboembolism
Stepwise vs Standard Anticoagulation for AF Patients Undergoing CIED Implantation (STEP-AF)
This is a multi-center, prospective, open-label, randomized controlled trial (STEP-AF) designed to evaluate the safety of a stepwise anticoagulation strategy compared with the guideline-recommended standard anticoagulation…
- Conditions
- Non-valvular Atrial Fibrillation (NVAF), Thromboembolism, Cardiac Implantable Electronic Device, Perioperative Bleeding
- Trial name
- STEP-AF (NCT07616414)
- Testing
- Stepwise Anticoagulation Regimen, Standard Anticoagulation Regimen
- Where
- China
- Volunteers
- 424 people
- Sponsor
- Fu Wai Hospital, Beijing, China
Non-valvular Atrial Fibrillation (NVAF), High Risk of Stroke
A Prospective, Single-arm Study Evaluating the Endothelialization Effect and Timeline of AnchorMan® Left Atrial Appendage Occluder in Non-valvular Atrial Fibrillation Patients at High Risk of Stroke
This study aims to evaluate the endotheliation efficacy of the AnchorMane® Left Atrial Appendage Occluder in non-valvular atrial fibrillation patients at high stroke risk.
- Trial name
- AnchorMan-NVAF (NCT07396493)
- Testing
- Intra-operative application of LAAC
- Volunteers
- 306 people
- Sponsor
- Shanghai Zhongshan Hospital
Non-valvular Atrial Fibrillation (NVAF)
A Study to Evaluate the Safety and Effectiveness of Rivaroxaban (Xarelto) for Prevention of Stroke and Systemic Embolism in Indian Patients With Non-valvular Atrial Fibrillation (NVAF)
This study is planned to collect prospective data and evaluate the safety and effectiveness of rivaroxaban for the prevention of stroke and systemic embolism in Indian patients with NVAF when used in clinical practice under…
- Trial name
- XARIN (NCT03887780)
- Testing
- Rivaroxaban (Xarelto,Bay 59-7939)
- Where
- India
- Volunteers
- 504 people
- Sponsor
- Bayer
Non-valvular Atrial Fibrillation (NVAF)
To Compare the Pharmacokinetics and Safety After a Single Dose Administration of IN-G00002 and IN-R00002 in Healthy Adult Volunteers
To compare the pharmacokinetics and safety after a single dose administration of IN-G00002 and IN-R00002 in healthy adult volunteers
- Trial name
- NCT06725355
- Testing
- IN-R00002, IN-G00002
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- HK inno.N Corporation
End-Stage Kidney Disease (ESKD), Non-valvular Atrial Fibrillation (NVAF)
The Safety and Effectiveness of Warfarin Vs Apixaban in Patients With NVAF/ VTE and ESKD on Dialysis
This is a retrospective study of End-Stage Kidney Disease (ESKD) patients on dialysis receiving apixaban or warfarin at Tawam Hospital [a tertiary care hospital in Al Ain, UAE].
- Conditions
- End-Stage Kidney Disease (ESKD), Non-valvular Atrial Fibrillation (NVAF), Venous Thromboembolism (VTE)
- Trial name
- WARD (NCT06606275)
- Testing
- Apixaban, Warfarin
- Where
- United Arab Emirates
- Volunteers
- 67 people
- Sponsor
- Abu Dhabi Health Services Company
Non-valvular Atrial Fibrillation (NVAF): Paroxysmal, Persistent, Permanent
Left Atrial Appendage Closure in Patients With Non-valvular Atrial Fibrillation and End-stage Chronic KIDNEY Disease
In the proposed event driven trial, LAA closure devices will be compared in a 1:1 randomization to best medical care in AF patients at high risk of stroke and bleeding with ESKD.
- Trial name
- LAA-KIDNEY (NCT05204212)
- Testing
- Left Atrial Appendage closure
- Where
- Germany
- Volunteers
- 430 people
- Sponsor
- Prof. Dr. med. Ingo Eitel
Non-valvular Atrial Fibrillation (NVAF)
Study to Gain Information on the Drug Xarelto for the Prevention of Brain Attack and Blockage of an Artery in the Non-central Nervous System Due to Irregular Heartbeat in Taiwanese Patients Suffering From Decreased Renal Function
In this study researchers want to learn more about on the safety of the drug Xarelto. The study will enroll patients for whom the treating doctor are prescribing Xarelto for the prevention of brain attack or the prevention of…
- Trial name
- XARETO (NCT04356989)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- Taiwan
- Volunteers
- 493 people
- Sponsor
- Bayer
Non-valvular Atrial Fibrillation (NVAF)
A Study to Learn Whether There Are Differences in the Kidney's Ability to Work Properly in Korean Patients With Non-valvular Atrial Fibrillation (Irregular and Often Rapid Heartbeat Not Caused by a Heart Valve Problem) Treated With Rivaroxaban as Compared to Those Treated With Warfarin
This is an observational study in which data collected from the past of patients with non-valvular atrial fibrillation (NVAF) is studied.
- Trial name
- RENOVATOR (NCT05022758)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Warfarin
- Where
- South Korea
- Volunteers
- 45,000 people
- Sponsor
- Bayer
Acute Coronary Syndrome (ACS), Non-valvular Atrial Fibrillation (NVAF)
Optimal Antithrombotic Therapy for ACS Patients Concomitant With AF and Implanted With New-generation DES (OPTIMA-3, 4)
It is a multi-center randomized clinical trial (RCT) which will enroll 3746 patients with acute coronary syndrome (ACS) concomitant non-valvular atrial fibrillation (NVAF) and undergoing new generation drug eluting stent (DES)…
- Trial name
- NCT03234114
- Testing
- Triple antithrombotic therapy, Dual antithrombotc therapy-1, Dual antithrombotc therapy-2
- Where
- China
- Volunteers
- 3,746 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Non-valvular Atrial Fibrillation (NVAF)
Xarelto on Prevention of Stroke and Non-Central Nervous Systemic Embolism in Renally Impaired Korean Patients With Non-valvular Atrial Fibrillation
The purpose of the study is to evaluate the safety and effectiveness of Xarelto in renally impaired patients with NVAF under routine practice conditions.
- Trial name
- XARENAL (NCT03746301)
- Testing
- Rivaroxaban(Xarelto,BAY 59-7939)
- Where
- South Korea
- Volunteers
- 924 people
- Sponsor
- Bayer
Non-valvular Atrial Fibrillation (NVAF), Chronic Kidney Disease (CKD)
Factor XA - Inhibition in RENal Patients With Non-valvular Atrial Fibrillation - Observational Registry
The multicenter registry will collect clinical data from 1600 patients with non valvular atrial fibrillation (NVAF) and chronic kidney disease (eGFR 15-49 mL/min per 1.73 m2).
- Trial name
- XARENO (NCT02663076)
- Where
- 121 sites in Austria, Belgium and 3 more
- Volunteers
- 1,700 people
- Sponsor
- GWT-TUD GmbH
Non-valvular Atrial Fibrillation (NVAF)
AMPLATZER™ Cardiac Plug Observational Post-Approval Study
The purpose of this study is to observe the safety and effectiveness of the AMPLATZER™ Cardiac Plug (ACP) device in Chinese population indicated for use of AMPLATZER™ Cardiac Plug after its market approval by China FDA (CFDA).
- Trial name
- ACP China (NCT02954237)
- Testing
- AMPLATZER™ Cardiac Plug
- Where
- 6 sites in China
- Volunteers
- 91 people
- Sponsor
- Abbott Medical Devices
Non-Valvular Atrial Fibrillation (NVAF)
A Study of Participants With Non-Valvular Atrial Fibrillation (NVAF) Treated or Untreated With Oral Anticoagulant in the National Cerebral and Cardiovascular Center (NCVC) in Japan
The purpose of this observational study is to understand real-world oral anticoagulants (OAC) (warfarin, apixaban, dabigatran, edoxaban and rivaroxaban) usage for non-valvular atrial fibrillation (NVAF) patients.
- Trial name
- NCT05027061
- Where
- Japan
- Volunteers
- 11,776 people
- Sponsor
- Bristol-Myers Squibb
Non-valvular Atrial Fibrillation (NVAF)
Xarelto [SPAF-QOL] Post-marketing Surveillance in Japan
The objective of this study is to understand if Rivaroxaban can improve treatment satisfaction of Warfarin patients and assess the safety and effectiveness of Xarelto in real clinical practice.
- Trial name
- NCT01598051
- Testing
- Rivaroxaban (Xarelto_ BAY59-7939)
- Where
- Japan
- Volunteers
- 741 people
- Sponsor
- Bayer
Non-valvular Atrial Fibrillation (NVAF)
Early Post-marketing Study of Eliquis (Apixaban)
The primary objective of the study is to identify and describe any suspected (AEs) in all patients with NVAF treated with Apixaban, as a request of the National Center of Pharmacovigilance (CNFV) in Mexico.
- Trial name
- NCT02153424
- Testing
- Apixaban
- Where
- 2 sites in Mexico
- Sponsor
- Bristol-Myers Squibb